1
|
Benvenutti L, Wolff FR, Corrêa TP, Melato J, Goldoni FC, De Faveri R, Patel YBK, de Souza JA, Grockoski HA, Nilz PM, Bombardelli CL, Remor AP, Varela KG, Costa NTC, Hernandes MZ, Lacerda MG, Rodrigues KD, Milton FA, Neves FDAR, Pereira MES, Kormann Imianowsky EC, de Campos Buzzi F, Brunaldi Marutani VH, Stoeberl LC, Correa R, Eller S, de Oliveira TF, Gonçalves TBP, da Silva RC, Passos GF, da Costa R, Santin JR, Quintão NLM. A partial agonist of PPARγ prevents paclitaxel-induced peripheral neuropathy in mice, by inhibiting neuroinflammation. Br J Pharmacol 2024; 181:1128-1149. [PMID: 37721089 DOI: 10.1111/bph.16244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 09/07/2023] [Accepted: 09/07/2023] [Indexed: 09/19/2023] Open
Abstract
BACKGROUND AND PURPOSE Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of paclitaxel, affecting 30-50% of patients. Increased survival and concern with patients' quality of life have encouraged the search for new tools to prevent paclitaxel-induced neuropathy. This study presents the glitazone 4-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-N-phenylbenzene-sulfonamide (TZD-A1) as a partial agonist of peroxisome proliferator-activated receptor γ (PPARγ), its toxicological profile and effects on paclitaxel-induced CIPN in mice. EXPERIMENTAL APPROACH Interactions of TZD-A1 with PPARγ were analysed using in silico docking and in vitro reporter gene assays. Pharmacokinetics and toxicity were evaluated using in silico, in vitro and in vivo (C57Bl/6 mice) analyses. Effects of TZD-A1 on CIPN were investigated in paclitaxel-injected mice. Axonal and dorsal root ganglion damage, mitochondrial complex activity and cytokine levels, brain-derived neurotrophic factor (BDNF), nuclear factor erythroid 2-related factor 2 (Nrf2) and PPARγ, were also measured. KEY RESULTS Docking analysis predicted TZD-A1 interactions with PPARγ compatible with partial agonism, which were corroborated by in vitro reporter gene assays. Good oral bioavailability and safety profile of TZD-A1 were shown in silico, in vitro and in vivo. Paclitaxel-injected mice, concomitantly treated with TZD-A1 by i.p. or oral administration, exhibited decreased mechanical and thermal hypersensitivity, effects apparently mediated by inhibition of neuroinflammation and mitochondrial damage, through increasing Nrf2 and PPARγ levels, and up-regulating BDNF. CONCLUSION AND IMPLICATIONS TZD-A1, a partial agonist of PPARγ, provided neuroprotection and reduced hypersensitivity induced by paclitaxel. Allied to its safety profile and good bioavailability, TZD-A1 is a promising drug candidate to prevent and treat CIPN in cancer patients.
Collapse
Affiliation(s)
- Larissa Benvenutti
- Postgraduate Program in Pharmaceutical Science, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Fellippe Ramos Wolff
- Postgraduate Program in Pharmaceutical Science, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Thiago Patrício Corrêa
- Postgraduate Program in Pharmaceutical Science, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Jessica Melato
- Postgraduate Program in Pharmaceutical Science, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Fernanda Capitanio Goldoni
- Postgraduate Program in Pharmaceutical Science, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Renata De Faveri
- Postgraduate Program in Pharmaceutical Science, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Yasmin Beatrisse Klein Patel
- Biomedicine, School of Health Sciences, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Jade André de Souza
- Biomedicine, School of Health Sciences, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Heloise Adeli Grockoski
- Biomedicine, School of Health Sciences, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Paulo Mateus Nilz
- Pharmacy Courses, School of Health Sciences, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Cleber Luiz Bombardelli
- Postgraduate Program in Pharmaceutical Science, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Aline Pertile Remor
- Postgraduate Program in Bioscience and Health, Universidade do Oeste de Santa Catarina (UNOESC), Joaçaba, Santa Catarina, Brazil
| | - Karina Giacomini Varela
- Postgraduate Program in Bioscience and Health, Universidade do Oeste de Santa Catarina (UNOESC), Joaçaba, Santa Catarina, Brazil
| | - Natáli Tereza Capistrano Costa
- Laboratório de Química Teórica e Medicinal (LQTM), Departamento de Ciências Farmacêuticas, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brazil
| | - Marcelo Zaldini Hernandes
- Laboratório de Química Teórica e Medicinal (LQTM), Departamento de Ciências Farmacêuticas, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brazil
| | - Mariella Guimarães Lacerda
- Laboratory of Molecular Pharmacology, Faculty of Health Sciences, University of Brasilia (UnB), Brasília, Distrito Federal, Brazil
| | - Kathlen Deruci Rodrigues
- Laboratory of Molecular Pharmacology, Faculty of Health Sciences, University of Brasilia (UnB), Brasília, Distrito Federal, Brazil
| | - Flora Aparecida Milton
- Laboratory of Molecular Pharmacology, Faculty of Health Sciences, University of Brasilia (UnB), Brasília, Distrito Federal, Brazil
| | - Francisco de Assis Rocha Neves
- Laboratory of Molecular Pharmacology, Faculty of Health Sciences, University of Brasilia (UnB), Brasília, Distrito Federal, Brazil
| | | | | | - Fátima de Campos Buzzi
- Postgraduate Program in Pharmaceutical Science, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Victor Hugo Brunaldi Marutani
- Laboratory of Animal Pathology, Department of Preventive Veterinary Medicine, Universidade Estadual de Londrina (UEL), Londrina, Paraná, Brazil
| | - Luis Carlos Stoeberl
- Postgraduate Program in Pharmaceutical Science, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Rogério Correa
- Postgraduate Program in Pharmaceutical Science, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Sarah Eller
- Graduate Program in Health Sciences, Federal University of Health Sciences of Porto Alegre (UFCSPA), Porto Alegre, Rio Grande do Sul, Brazil
| | - Tiago Franco de Oliveira
- Graduate Program in Health Sciences, Federal University of Health Sciences of Porto Alegre (UFCSPA), Porto Alegre, Rio Grande do Sul, Brazil
| | | | - Raquel Costa da Silva
- School of Pharmacy, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil
| | - Giselle Fazzioni Passos
- School of Pharmacy, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil
| | - Robson da Costa
- School of Pharmacy, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil
| | - José Roberto Santin
- Postgraduate Program in Pharmaceutical Science, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| | - Nara Lins Meira Quintão
- Postgraduate Program in Pharmaceutical Science, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil
| |
Collapse
|
2
|
Abstract
Manganese (Mn) is an abundant element used for commercial purposes and is essential for the proper function of biological systems. Chronic exposure to high Mn concentrations causes Manganism, a Parkinson's-like neurological disorder. The pathophysiological mechanism of Manganism remains unknown; however, it involves mitochondrial dysfunction and oxidative stress. This study assessed the neuroprotective effect of probucol, a hypolipidemic agent with anti-inflammatory and antioxidant properties, on cell viability and oxidative stress in slices of the cerebral cortex and striatum from adult male Wistar rats. Brain structure slices were kept separately and incubated with manganese chloride (MnCl2) and probucol to evaluate the cell viability and oxidative parameters. Probucol prevented Mn toxicity in the cerebral cortex and striatum, as evidenced by the preservation of cell viability observed with probucol (10 and 30 μM) pre-treatment, as well as the prevention of mitochondrial complex I inhibition in the striatum (30 μM). These findings support the protective antioxidant action of probucol, attributed to its ability to prevent cell death and mitigate Mn-induced mitochondrial dysfunction.
Collapse
Affiliation(s)
| | - Karina Giacomini Varela
- Programa de Pós-Graduação em Biociências e Saúde (PPGBS), Área de Ciências da Vida e Saúde, Universidade do Oeste de Santa Catarina (UNOESC), Joaçaba, Brazil
| | - Diego de Carvalho
- Programa de Pós-Graduação em Biociências e Saúde (PPGBS), Área de Ciências da Vida e Saúde, Universidade do Oeste de Santa Catarina (UNOESC), Joaçaba, Brazil
| | - Aline Pertile Remor
- Programa de Pós-Graduação em Biociências e Saúde (PPGBS), Área de Ciências da Vida e Saúde, Universidade do Oeste de Santa Catarina (UNOESC), Joaçaba, Brazil
| |
Collapse
|
3
|
da Silva EB, Eichwald T, Glaser V, Varela KG, Baptistella AR, de Carvalho D, Remor AP. Protective Effects of Probucol on Different Brain Cells Exposed to Manganese. Neurotox Res 2022; 40:276-285. [PMID: 35043377 DOI: 10.1007/s12640-021-00458-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 11/11/2021] [Accepted: 12/03/2021] [Indexed: 10/19/2022]
Abstract
Manganese (Mn) is an essential metal for many functions in the body. However, in excess, it can be neurotoxic and cause a Parkinson-like syndrome, known as manganism. Here, we aimed to identify a protective effect of probucol, a lipid-lowering agent with anti-inflammatory and antioxidant properties, against Mn-induced toxicity in human neuroblastoma (SH-SY5Y) and glioblastoma (C6) cell lines. The cells were incubated with increasing concentrations of Mn followed by probucol addition 1, 3, 6, and/or 24 h to assess the metal toxic doses and measure the protective effect of probucol against Mn-induced oxidative damage. Longer exposition to Mn showed decreased SH-SY5Y cellular viability in concentrations higher than 100 µM, and probucol was able to prevent this effect. The C6 cells were more sensitive to the Mn deleterious actions, decreasing the cell viability after 6 h of 500 µM Mn exposure. In addition, probucol prevents the complex I and II of the mitochondrial respiratory chain (MRC) inhibition caused by Mn and decreased the intracellular ROS production. Taken together, our results showed that Mn toxicity affects differently both cell lines and probucol has a protective effect against the oxidative imbalance in the central nervous system.
Collapse
Affiliation(s)
- Erica Blenda da Silva
- Graduada em Medicina, Área de Ciências da Vida e Saúde, Universidade do Oeste de Santa Catarina (UNOESC), Campus de Joaçaba, SC, 89600-000, Joaçaba, Brazil
| | - Tuany Eichwald
- Programa de Pós-Graduação em Biociências e Saúde (PPGBS), Área de Ciências da Vida e Saúde, Universidade do Oeste de Santa Catarina (UNOESC), Campus de Joaçaba, SC, 89600-000, Joaçaba, Brazil
| | - Viviane Glaser
- Centro de Ciências Rurais, Coordenadoria Especial de Ciências Biológicas e Agronômicas, Universidade Federal de Santa Catarina (UFSC), Campus de Curitibanos, SC, Curitibanos, Brazil
| | - Karina Giacomini Varela
- Graduada em Ciências Biológicas, Universidade do Oeste de Santa Catarina (UNOESC), Campus de Joaçaba, Biotério, 89600-000, Joaçaba, Brazil
| | - Antuani Rafael Baptistella
- Programa de Pós-Graduação em Biociências e Saúde (PPGBS), Área de Ciências da Vida e Saúde, Universidade do Oeste de Santa Catarina (UNOESC), Campus de Joaçaba, SC, 89600-000, Joaçaba, Brazil
| | - Diego de Carvalho
- Programa de Pós-Graduação em Biociências e Saúde (PPGBS), Área de Ciências da Vida e Saúde, Universidade do Oeste de Santa Catarina (UNOESC), Campus de Joaçaba, SC, 89600-000, Joaçaba, Brazil
| | - Aline Pertile Remor
- Programa de Pós-Graduação em Biociências e Saúde (PPGBS), Área de Ciências da Vida e Saúde, Universidade do Oeste de Santa Catarina (UNOESC), Campus de Joaçaba, SC, 89600-000, Joaçaba, Brazil.
| |
Collapse
|